1. Home
  2. CPSS vs URGN Comparison

CPSS vs URGN Comparison

Compare CPSS & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CPSS
  • URGN
  • Stock Information
  • Founded
  • CPSS 1991
  • URGN 2004
  • Country
  • CPSS United States
  • URGN United States
  • Employees
  • CPSS N/A
  • URGN N/A
  • Industry
  • CPSS Finance: Consumer Services
  • URGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • CPSS Finance
  • URGN Health Care
  • Exchange
  • CPSS Nasdaq
  • URGN Nasdaq
  • Market Cap
  • CPSS 193.8M
  • URGN 181.2M
  • IPO Year
  • CPSS 1992
  • URGN 2017
  • Fundamental
  • Price
  • CPSS $9.77
  • URGN $14.24
  • Analyst Decision
  • CPSS
  • URGN Strong Buy
  • Analyst Count
  • CPSS 0
  • URGN 8
  • Target Price
  • CPSS N/A
  • URGN $29.00
  • AVG Volume (30 Days)
  • CPSS 23.3K
  • URGN 4.2M
  • Earning Date
  • CPSS 07-29-2025
  • URGN 08-12-2025
  • Dividend Yield
  • CPSS N/A
  • URGN N/A
  • EPS Growth
  • CPSS N/A
  • URGN N/A
  • EPS
  • CPSS 0.79
  • URGN N/A
  • Revenue
  • CPSS $188,776,000.00
  • URGN $91,871,000.00
  • Revenue This Year
  • CPSS $146.82
  • URGN $36.65
  • Revenue Next Year
  • CPSS $18.24
  • URGN $88.35
  • P/E Ratio
  • CPSS $12.32
  • URGN N/A
  • Revenue Growth
  • CPSS N/A
  • URGN 8.98
  • 52 Week Low
  • CPSS $7.99
  • URGN $3.42
  • 52 Week High
  • CPSS $12.73
  • URGN $18.15
  • Technical
  • Relative Strength Index (RSI)
  • CPSS 58.96
  • URGN 64.26
  • Support Level
  • CPSS $9.79
  • URGN $13.55
  • Resistance Level
  • CPSS $10.18
  • URGN $14.66
  • Average True Range (ATR)
  • CPSS 0.29
  • URGN 0.83
  • MACD
  • CPSS -0.02
  • URGN -0.08
  • Stochastic Oscillator
  • CPSS 74.14
  • URGN 73.66

About CPSS Consumer Portfolio Services Inc.

Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: